COMMANDS: Long-Term Analysis, Changes in RBC Transfusion Burden, Hemoglobin Levels and ELEMENTS Trial

Panelists discuss how long-term analysis of the ELEMENTS trial reveals significant improvements in red blood cell (RBC) transfusion burden and hemoglobin levels among study participants.

CN24_FO_MDS_Seg01_COMMANDS

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

Now Viewing

EP: 1.COMMANDS: Long-Term Analysis, Changes in RBC Transfusion Burden, Hemoglobin Levels and ELEMENTS Trial

EP: 2.MEDALIST and IMerge Trial Presentation and Discussion

EP: 3.Debate: Do We Treat First With ESAs or With Luspatercept?

EP: 4.Do We Start Luspatercept at the Highest Dose and Titrate Down or Start Low and Titrate Up?

EP: 5.Clinical Scenario: Patient Receiving First-Line ESA Without a Marked Response: What Do You Do Next?

EP: 6.Clinical Scenario: How Do We Treat Patients With Ring Sideroblast/Genetic Abnormalities?

Recent Videos

Second-Line Treatment for Gastric Adenocarcinoma

Advanced Metastatic Gastric Adenocarcinoma: Treatment Approaches

Gastric Adenocarcinoma: Current Treatment Landscape

Adjuvant Nivolumab in Gastric Cancers & CheckMate 8HW

Esophageal/Gastric Adenocarcinoma Standard of Care

BESPOKE: Study Design, Efficacy End Points and Methods

The Role of ctDNA in CRC

CAR T in High-Risk DLBCL: Making the Right Choice in Aggressive Disease

PSMA PET Imaging Agents: Image Quality and Diagnostic Performance

KEYMAKER-U03: Lenvatinib Plus Belzutifan Emerges as a Promising Option in Advanced RCC and New Directions From ASCO GU 2025